Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2022 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
November 07, 2022 08:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics to Present at Sidoti Virtual Investor Conference

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
October 26, 2022 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
October 13, 2022 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
September 27, 2022 08:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference

BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
September 08, 2022 08:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
August 15, 2022 16:15 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
August 02, 2022 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology

BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson...
July 11, 2022 16:05 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its...
June 09, 2022 09:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics to Participate at BIO International Convention

BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right